InMed files CTA to start second Phase 1 INM-755 clinical trial
Category: #health  By Nikita Chaurasia  Date: 2020-03-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

InMed files CTA to start second Phase 1 INM-755 clinical trial

InMed Pharmaceuticals Inc., a leading biopharmaceutical company which develops medications targeting diseases with unmet needs, has reportedly announced the filing of CTA (Clinical Trial Application) in the Netherlands to commence a second Phase 1 trial in humans to assess INM-755 in healthy subjects.

755-102-HV is a Phase 1 study which is double-blind, randomized, as well as vehicle-controlled. It is designed to assess the tolerability and safety of INM-755 cream being applied on a daily basis on epidermal wounds in healthy volunteers. Overall, two strengths of the INM-755 cream would be assessed over a 14-day treatment period in 8 adult subjects.

Alexandra Mancini, Senior VP, Clinical and Regulatory Affairs, InMed, stated that the second Phase 1 trial is another essential step towards the efficacy trials of INM-755.

Mancini further stated that the review of the CTA application would continue as usual in spite of the restrictions in place in the Netherlands due to the COVID-19 epidemic. The enrollment would begin soon as the CTA is approved, and the restrictions are lifted.

About InMed Pharmaceuticals:

InMed Pharmaceuticals is a biopharmaceutical company specializing in the discovery as well as development of new cannabinoid-based therapeutics for illnesses with significant unmet medical need. The firm is focused on the creation of new therapeutic substitutes to patients that might benefit from medicines that are cannabinoid based.

The firm takes on a highly scientific approach for designing and developing medicines, which further aids in unlocking the full potential of cannabinoid pharmaceuticals.

About INM-755:

INM-755 is CBN cream which is proposed as a topical therapy for the treatment of EB (epidermolysis bullosa) and possibly other dermatological diseases. The preclinical data signifies that INM-755 might help alleviate hallmark EB symptoms like pain and inflammation and possibly reinstate the integrity of the skin in a subgroup of EB simplex patients.

Source credit: https://finance.yahoo.com/news/inmed-submits-clinical-trial-application-113000611.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...